Skip to main content
TipRanks
Go Ultimate75% OFF

Xintela AB (XINT) AI Stock Analysis

0 Followers
SE:XINT

Xintela AB

(Nasdaq OMX AB:XINT)

Select Model
Rating:42Neutral
Price Target:SEK 0.13â–¼(-3.60% Downside)
Action:reiterated
Date:09/25/26

The score is primarily weighed down by very large operating losses, substantial ongoing cash burn, and negative equity alongside debt, which together raise financing and dilution risk. Technicals are mixed (below key longer-term averages with negative MACD), and valuation signals are limited because the company is loss-making and has no provided dividend yield.

Positive Factors
Revenue GrowthRevenue growth indicates that Xintela is expanding its current commercial or development-related revenue base despite operating at an early stage. Continued topline progress can improve funding capacity and provide validation for advancing its pipeline over the next several quarters.
Negative Factors
Severe Operating LossesThe scale of current losses is far larger than the revenue base, showing that Xintela has not yet reached an economically sustainable operating model. Persistent losses can consume capital rapidly and make future performance highly dependent on successful pipeline advancement or external funding.

Xintela AB (XINT) vs. iShares MSCI Sweden ETF (EWD)

-60%-40%-20%0%20%40%SE:XINT-45.70%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 120.15M
Dividend Yield
―
Average Volume (3M)
233.29K
Price to Earnings (P/E)
-2.4
Beta (1Y)
0.36
Revenue Growth
-38.46%
EPS Growth
9.02%
Country
Sweden
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (publ), a biomedical company established in 2009 in Lund, Sweden, concentrates its efforts on two key areas: regenerative medicine, particularly for cartilage repair, and oncology, with a focus on brain tumors. Central to their work is XIN...

How the Company Makes Money

Xintela’s monetization is primarily intended to come from advancing its ITGA10-based programs and capturing value through partnering and commercialization. Key expected revenue streams include: (1) out-licensing or co-development deals for its drug a...

Xintela AB Financial Statement Overview

Summary

Revenue is growing (TTM 3.03M, +17.2%) with a strong gross margin (~82%), but the business remains severely unprofitable (TTM net loss -47.7M; net margin ~-1,575%) with heavy cash burn (TTM OCF -47.4M; FCF -38.3%). Balance sheet risk is elevated with negative equity (-27.2M) alongside meaningful debt (30.0M), increasing financing/dilution risk.

Income Statement

18Very Negative

Balance Sheet

22Negative

Cash Flow

16Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.03M2.28M4.21M78.00K00
Gross Profit2.50M1.68M4.21M78.00K-3.79M-3.50M
EBITDA-45.47M-46.08M-38.90M-53.47M-64.83M-57.18M
Net Income-47.72M-48.56M-39.19M-54.08M-66.22M-58.93M
Balance Sheet
Total Assets35.10M29.02M24.80M18.39M24.52M24.74M
Cash, Cash Equivalents and Short-Term Investments30.72M23.21M16.68M7.81M8.34M9.94M
Total Debt30.00M20.00M0000
Total Liabilities62.33M34.30M30.75M14.02M18.74M20.80M
Stockholders Equity-27.23M-5.27M-5.95M4.38M5.78M3.95M
Cash Flow
Free Cash Flow-38.28M-41.62M-40.70M-53.22M-39.60M-44.15M
Operating Cash Flow-47.42M-41.62M-40.70M-53.12M-39.49M-42.89M
Investing Cash Flow70.00K00-104.00K-27.52M-1.20M
Financing Cash Flow68.40M48.53M50.09M51.79M64.56M20.43M

Xintela AB Technical Analysis

Technical Analysis SentimentNegative
Last Price0.14

Price Trends

50DMA0.16Negative
100DMA0.17Negative
200DMA0.21Negative

Market Momentum

MACD-0.01Positive
RSI34.83Neutral
STOCH23.50Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.16, and below the 200-day MA of 0.21, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 34.83 is Neutral, neither overbought nor oversold. The STOCH value of 23.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XINT.

Xintela AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:XINT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ISOFOLSE:ISOFOL48NeutralSEK 339.08M-5.64-58.68%――35.02%
SE:ELICSE:ELIC47NeutralSEK 166.84M-7.07-56.09%――14.10%
SE:NXTCLSE:NXTCL46NeutralSEK 28.63M-0.59-81.23%―-4.02%35.86%
SE:XBRANESE:XBRANE46NeutralSEK 219.45M-5.89-11.52%―-38.80%-120.18%
SE:ACTISE:ACTI44NeutralSEK 92.53M-5.01-85.07%――51.09%
SE:XINTSE:XINT42NeutralSEK 120.15M-2.38245.07%―-38.46%9.02%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:XINTSE:XBRANESE:ISOFOLSE:ELICSE:ACTISE:NXTCLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:XINT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:XINTXintela AB0.14-0.12-46.54%
SE:XBRANEXbrane Biopharma AB10.650.706.98%
SE:ISOFOLIsofol Medical AB1.060.3651.36%
SE:ELICElicera Therapeutics AB2.50-2.78-52.66%
SE:ACTIActive Biotech AB3.51-2.60-42.54%
SE:NXTCLNextCell Pharma AB0.23-0.56-71.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 25, 2026